echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Blood: A new prognostic prediction scoring system for extranodal natural killer/T cell lymphoma!

    Blood: A new prognostic prediction scoring system for extranodal natural killer/T cell lymphoma!

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Extranodal natural killer/T-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin's lymphoma, characterized by Epstein-Barr virus infection , mainly involving the nasal cavity and nasopharynx


    Lymphoma infection

    However, the current prognostic scoring system based on clinicopathological variables cannot well predict the treatment response and survival time of patients with extranodal natural killer/T-cell lymphoma (ENKTL) using non-anthracycline-based treatment


    This study aims to establish based on single nucleotide polymorphism (SNP) of the separator in order to improve the prediction accuracy of the guide clinical decision making


    Based on single nucleotide polymorphism (SNP) of the separator in order to improve the prediction accuracy of the guide clinical decision making based on single nucleotide polymorphism (SNP) of the separator in order to improve the prediction accuracy of the guide clinical decision making accurate

    LASSO logistic regression model identified 7 SNPs

    LASSO logistic regression model identified 7 SNPs

    Using the LASSO logistic regression model , a classifier (7-SNP classifier) based on 7 SNPs ( rs3734905, rs10272776, rs3860783, rs17776928, rs73639447, rs10844247, rs3122712 ) was established in the training queue , and obtained in 3 validation queues Verification


    rs3734905, rs10272776, rs3860783, rs17776928, rs73639447, rs10844247, rs3122712 rs3734905, rs10272776, rs3860783, rs17776928, rs73639447, rs10844247, rs3122712 Progression-free survival (PFS) and overall survival of patients with high-risk and low-risk scores according to this classifier Period (OS) showed significant difference (p<0.


    Its prediction accuracy is significantly better than clinicopathological risk variables.


    Ann Arbor stage I patients with different risks are treated with PFS and OS combined with radiotherapy and chemotherapy or radiotherapy alone

    Ann Arbor stage I patients with different risks are treated with PFS and OS combined with radiotherapy and chemotherapy or radiotherapy alone

    It is worth noting that the PFS and OS of high-risk Ann Arbor stage I patients with combined radiotherapy and chemotherapy are significantly better than radiotherapy alone, but in low-risk patients, there is no statistically significant difference in the prognosis of the two regimens


    The PFS and OS of high-risk Ann Arbor stage I patients with combined radiotherapy and chemotherapy were significantly better than those with radiotherapy alone, but in low-risk patients, the prognosis of the two regimens was not statistically different.


    The 7-SNP-based classifier is a supplement to ENKTL's existing risk stratification system and may be of great significance to the clinical decision-making of ENKTL patients.


    Original source:

    Xiao-Peng Tian, ​​et al.


    A composite single-nucleotide polymorphism prediction signature for extranodal natural killer / T-cell lymphoma

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.